Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 5/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.48 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.48 |
| ▸ | NQO1 | P15559 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 8/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780759 | 0.92 | MAOB (0.56) | MAOACASP3SENP8SENP7SENP6 | |
| SCHEMBL2761688 | 0.84 | L3MBTL1 (0.52) | L3MBTL1PKMMAOACASP3SENP8 | |
| SCHEMBL2762010 | 0.83 | L3MBTL1 (0.58) | L3MBTL1PKMMAOACASP3SENP8 | |
| SCHEMBL2761412 | 0.82 | MAOA (0.56) | PKMMAOACASP3SENP8SENP7 | |
| SCHEMBL2761411 | 0.82 | MAOA (0.56) | PKMMAOACASP3SENP8SENP7 | |
| SCHEMBL2762048 | 0.77 | MAOB (0.46) | CASP3SENP8SENP7SENP6MAP1LC3B | |
| SCHEMBL2761626 | 0.76 | MAOB (0.57) | MAOACASP3SENP8SENP7SENP6 | |
| SCHEMBL2762426 | 0.76 | ANO1 (0.50) | L3MBTL1PKMCASP3SENP8SENP7 | |
| SCHEMBL2761681 | 0.74 | MAOB (0.62) | MAOACASP3SENP8SENP7SENP6 | |
| SCHEMBL11848551 | 0.74 | PKM (0.52) | L3MBTL1PKMMAOACASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | HIF1AN, HIF1A, EGLN2 | L3MBTL1 3898/4885PKM 814/4885MAOA 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.